LS60 Stock Overview
Engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Clinical Laserthermia Systems AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.32 |
| 52 Week High | SEK 7.80 |
| 52 Week Low | SEK 0.04 |
| Beta | 0.21 |
| 11 Month Change | -17.17% |
| 3 Month Change | -24.20% |
| 1 Year Change | -75.91% |
| 33 Year Change | -99.61% |
| 5 Year Change | -99.83% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| LS60 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 16.9% | 3.8% | 1.3% |
| 1Y | -75.9% | -6.6% | 7.9% |
Return vs Industry: LS60 underperformed the German Medical Equipment industry which returned -5.7% over the past year.
Return vs Market: LS60 underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| LS60 volatility | |
|---|---|
| LS60 Average Weekly Movement | 21.6% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LS60's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LS60's weekly volatility has decreased from 195% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 17 | Dan Mogren | www.clinicallaser.se |
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment.
Clinical Laserthermia Systems AB (publ) Fundamentals Summary
| LS60 fundamental statistics | |
|---|---|
| Market cap | €5.27m |
| Earnings (TTM) | -€5.57m |
| Revenue (TTM) | €1.62m |
3.3x
P/S Ratio-0.9x
P/E RatioIs LS60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LS60 income statement (TTM) | |
|---|---|
| Revenue | SEK 18.63m |
| Cost of Revenue | SEK 11.53m |
| Gross Profit | SEK 7.10m |
| Other Expenses | SEK 71.30m |
| Earnings | -SEK 64.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -4.61 |
| Gross Margin | 38.09% |
| Net Profit Margin | -344.68% |
| Debt/Equity Ratio | 2.0% |
How did LS60 perform over the long term?
See historical performance and comparison